Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genmab ( (GMAB) ) has issued an announcement.
On April 14, 2026, Genmab reported that Johnson & Johnson’s Janssen unit recorded worldwide net trade sales of USD 3,964 million for the blood cancer drug DARZALEX in the first quarter of 2026, including its subcutaneous DARZALEX FASPRO formulation. Sales reached USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world, cementing DARZALEX as a major revenue driver in the multiple myeloma treatment market.
Under its exclusive worldwide license agreement, Genmab receives royalties on all intravenous and subcutaneous DARZALEX sales, meaning the strong first-quarter performance directly supports the Danish biotech’s royalty income and financial firepower. The robust uptake underscores Genmab’s entrenched position in antibody-based oncology, with sustained DARZALEX momentum likely to bolster investment capacity for its expanding late-stage pipeline and future product launches.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, Denmark, the company has built a broad portfolio of antibody-based formats, including bispecifics and antibody–drug conjugates, powering eight approved therapies and a strong late-stage clinical pipeline across North America, Europe and Asia Pacific.
Average Trading Volume: 1,729,892
Technical Sentiment Signal: Hold
Current Market Cap: $17.36B
For an in-depth examination of GMAB stock, go to TipRanks’ Overview page.